Receive The Newest Study Notifications

IRVINE, Calif., Dec. 5, 2019 /PRNewswire-PRWeb/ -- StudyKIK, a patient recruitment and technology company that builds digital patient communities and enrollment technology solutions for clinical trials, has launched an e-consent solution with seamless integration to...

RYE BROOK, N.Y., Dec. 6, 2019 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and the American Society of Hematology (ASH) announced today a collaboration to expand access to LLS's unique free service providing clinical trials navigation and support to blood...

Patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease and a leading cause for liver transplantation in the U.S., currently lack an approved drug therapy, but this may soon change. A large Phase III clinical trial designed in collaboration with...

BOSTON, Dec. 5, 2019 /PRNewswire/ -- EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today announced that the efficacy and safety data from the REVERSE-SD clinical study were presented at the Clinical Trials in Alzheimer's Disease (CTAD)...

Enrollment in the Phase 2 clinical trial of setanaxib (GKT831), an oral investigational treatment for idiopathic pulmonary fibrosis (IPF), will start in the coming weeks, Genkyotex announced in a progress report. Following approval by the U.S. Food and Drug...

First NIH-funded clinical trial in the US using umbilical cord derived mesenchymal stem cells for the treatment of patients with new onset type 1 diabetes Type 1 diabetes (T1D) is a chronic condition in which the body's own immune system attacks and destroys beta...

SYDNEY--(BUSINESS WIRE)--NeuClone Pharmaceuticals Ltd (NeuClone), a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced that NeuCeptin, a biosimilar candidate of Herceptin® (trastuzumab), has...

BOSTON--(BUSINESS WIRE)-- Cerevance a clinical stage biopharmaceutical company advancing new medicines for brain diseases, announced today the initiation of a Phase 2 clinical trial of CVN424, an oral, first-in-class compound that selectively modulates a novel,...

NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders...

SPRING HOUSE, Pa., Dec. 4, 2019 /PRNewswire/ -- Cognizance Biomarkers, LLC, a wholly-owned subsidiary of Evogen Inc., a leader in proteomic and genomic-based testing for improved diagnosis and treatment of neurological disorders, today announced initiation of a...

GUANGZHOU, China--(BUSINESS WIRE)-- Bio-Thera Solutions, Ltd., a clinical-stage pharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application to initiate a Phase I...

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today presented positive top-line results from its Phase 3 HARMONY study at the 12 th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting, December 4 -7, 2019 in San Diego, California. HARMONY was a double-blind,...

-- Topline data expected in the fourth quarter of 2020 or early in the first quarter of 2021 -- -- Supplemental cohort continues enrollment to meet patient demand -- BOSTON, Dec. 05, 2019 (GLOBE NEWSWIRE) --  Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a...

PHILADELPHIA, Dec. 4, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced positive results from the first human study evaluating insulin glargine that Lannett is developing with its strategic alliance partners within the HEC Group of companies...

ENGLEWOOD, Colo., Dec. 4, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled  "Evaluating the Efficacy and Safety of...

NEW YORK, Dec. 4, 2019  Eolas Therapeutics Inc. today announced the initiation of a Phase I study of AZD4041 for treating tobacco use and dependence. The study will investigate safety and pharmacokinetics (PK) of AZD4041 in healthy volunteers. AZD4041 is a central...

London, UK, 4 December 2019: The first UK clinical trial site for the treatment of diabetic patients with chronic limb-threatening ischemia (CLI) using a novel patient-specific regenerative therapy has opened for patient recruitment at the University Hospital of Wales...

 PDC-1421, the active ingredient of ABV-1505, is being expanded into adult ADHD trials following encouraging Phase II trial results in major depressive disorder (MDD)  Phase II Part I trial of ABV-1505 to be conducted at the University of California, San Francisco...

LA JOLLA, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that additional analyses of...

First indication of human safety and PK profiles for SPR720 supports advancement of program to a Phase 2a proof-of-concept clinical trial in patients planned to initiate in the second half of 2020 CAMBRIDGE, MA, USA I December 04, 2019 I Spero Therapeutics, Inc....